Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American

NCT ID: NCT05184504

Last Updated: 2025-02-12

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 211 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-09-01
• Study Completion Date: 2024-07-11

Brief Summary

Observational study, retrospective and prospective, of an analytical nature. Data will be collected from medical records and/or through contact with physicians and institutions (secondary data collection). Patients included retrospectively or prospectively will be followed during the data collection period for the evaluation of treatments and survival. No intervention is planned in this protocol.

Conditions

Kidney Neoplasms

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Study Groups

Patients with pathological diagnosis of renal cell carcinoma

Patients aged 18 years or older, who have been diagnosed with renal cell carcinoma (new case or recurrence) since January 2015 and during the study recruitment period.

Observational study

Intervention Type: OTHER

This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Interventions

Observational study

This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Patients ≥ 18 years of age;
• Proven histology of renal cell carcinoma (any subtype);
• Pathological diagnosis of renal cell carcinoma in January 2015 or later and new cases diagnosed during the period of recruitment of each center;
• Have the medical record available and suitable for collecting data on patient characteristics, treatment and outcome.

Exclusion Criteria

• Synchronous or other primary tumor within the last 3 years (except thyroid cancer or non melanoma skin).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ipsen

INDUSTRY

Sponsor Role: collaborator

Latin American Cooperative Oncology Group

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

André Poisl Fay

Role: PRINCIPAL_INVESTIGATOR

Latin American Cooperative Oncology Group

Locations

CINPAM - Centro Integrado de Pesquisa da Amazônia

Manaus, Amazonas, Brazil

Oncocentro Ceará (Rede D'or)

Fortaleza, Ceará, Brazil

Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO)

Cachoeiro de Itapemirim, Espírito Santo, Brazil

Santa Casa de Misericórdia de Feira de Santana

Feira de Santana, Estado de Bahia, Brazil

NOB - Núcleo de Oncologia da Bahia (Oncoclínicas)

Salvador, Estado de Bahia, Brazil

Onco-Vida Instituto Especializado de Oncologia

Brasília, Federal District, Brazil

Hospital do Câncer do Maranhão Dr. Tarquínio Lopes Filho

São Luís, Maranhão, Brazil

Clinica Prognóstica - Centro de Pesquisa Clínica Onconeo

Campo Grande, Mato Grosso do Sul, Brazil

ICTR - Instituto do Câncer e Transplante de Curitiba

Curitiba, Paraná, Brazil

Hospital Napoleão Laureano

João Pessoa, Paraíba, Brazil

Hospital Porto Dias

Belém, Pará, Brazil

CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS

Porto Alegre, Rio Grande do Sul, Brazil

Clínica de Hematologia e Oncologia Viver

Santa Maria, Rio Grande do Sul, Brazil

CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas)

Rio de Janeiro, , Brazil

Hemomed Instituto de Oncologia e Hematologia

São Paulo, , Brazil

CPO - Centro Paulista de Oncologia (Oncoclínicas)

São Paulo, , Brazil

Countries

Brazil

Other Identifiers

LACOG 1120

Identifier Type: -

Identifier Source: org_study_id